Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy.

Qi WangQingfa BuZibo XuYuan LiangJinren ZhouYufeng PanHaoming ZhouLing Lu

Published in: Clinical and molecular hepatology (2024)

ATG16L1 suppresses MASH progression by maintaining macrophage lipophagy, restraining liver inflammation, and may be a promising therapeutic target for MASH management.

Keyphrases

oxidative stress
signaling pathway
adipose tissue
poor prognosis
binding protein
liver fibrosis